论文部分内容阅读
目的:本研究旨在探讨质子泵抑制剂(PPI)对心内科拟诊断为冠心病患者的嗜铬粒蛋白A(CgA)水平影响的临床意义。方法:113名拟诊冠心病的住院患者,分为PPI组(药物治疗中加入PPI,共62例)和非PPI组(药物治疗中无PPI,共51例),收集其外周血清,用ELISA法检测样本血清中CgA水平,同时应用化学发光法检测样本血清中NT-proBNP水平。比较PPI组和非PPI组CgA、NT-proBNP水平的差异。结果:因为CgA、NT-proBNP均为非正态分布资料,两者均通过对数转换为正态分布资料;PPI组的LN CgA的均数显著高于非PPI组(4.62±0.97和3.91±0.89,P=0.000)。而两组LN NT-proBNP的均数无显著差异(5.41±1.46和5.59±2.00,P=0.580)。结论:在心功能等临床特征具有可比性的情况下,是否使用PPI对CgA水平的影响很大;而对BNP无明显影响。评价CgA在心功能分级或冠心病预后等方面的应用,不能忽略PPI联用对CgA数值的影响。
Objective: This study was designed to investigate the clinical significance of the effect of proton pump inhibitor (PPI) on the level of chromogranin A (CgA) in patients with coronary heart disease to be diagnosed as coronary heart disease. Methods: A total of 113 hospitalized patients with CHD were divided into PPI group (PPI, 62 cases) and non-PPI group (51 cases without PPI) .Serum samples were collected by ELISA Method to detect the level of serum CgA in the sample, meanwhile, the level of NT-proBNP in the sample serum was detected by chemiluminescence method. The differences of CgA, NT-proBNP between PPI group and non-PPI group were compared. Results: Because both CgA and NT-proBNP were non-normal distribution data, both of them were converted to normal distribution data by logarithm. Mean LN CgA in PPI group was significantly higher than that in non-PPI group (4.62 ± 0.97 and 3.91 ± 0.89, P = 0.000). There was no significant difference in mean LN NT-proBNP between the two groups (5.41 ± 1.46 and 5.59 ± 2.00, P = 0.580). CONCLUSION: The use of PPI has a significant effect on CgA levels with comparable clinical features such as cardiac function, but no significant effect on BNP. Evaluation of CgA in the classification of cardiac function or coronary heart disease prognosis and other aspects of the application of PPI can not ignore the effect of CgA values.